Page 5 - Biophys Res News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Daiichi Sankyo Company, Limited: Datopotamab Deruxtecan and ENHERTU Show Promising Early Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer
ii
80% (n=64)
CI, confidence interval; CR, complete response; DCR, disease control rate; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR, partial response
i Includes patients with =1 postbaseline scan or who discontinued treatment.
ii ORR is CR+PR; Responses are confirmed (CRs/PRs; n=32) plus those CRs/PRs too early to be confirmed (n=5).
iii DCR is CR+PR+SD
iv Preliminary PFS limited by earlier censoring by data cutoff due to immature duration of follow-up for 4 and 6 mg/kg dose cohorts. ....

United States , Japan General , Nat Genet , Masashi Kawase , Daiichi Sankyo , Daiichi Sankyo Europe Gmb , Cristian Massacesi , Don Murphy , Alexander Spira , Antoine Yver , Plexxikon Inc , Daiichi Sankyo Company , American Society Of Clinical Oncology , Daiichi Sankyo Inc , World Health Organization , Clinical Development Program , Oncology Research , Daiichi Sankyo Co Ltd , Datopotamab Deruxtecan Clinical Development Program , National Comprehensive Care Network , International Agency For Research On Cancer , Us Oncology Research , Daiichi Sankyo Group , Head Of Late Stage Development , World Conference , Lung Cancer ,